WORLD HEALTH ENERGY HOLDINGS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that WORLD HEALTH ENERGY HOLDINGS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $0 | Aug 15, 2018 |
| FY2016 | Dec 31, 2015 | $0 | Aug 15, 2018 |
| FY2011 | Dec 31, 2011 | $0 | Apr 2, 2012 |
| FY2011 | Dec 31, 2010 | $0 | Apr 2, 2012 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $166.0K | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | $207.7K | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $91.1K | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $140.2K | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $98.2K | Apr 14, 2022 |
| FY2020 | Dec 31, 2019 | $104.0K | Apr 15, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $62.7K | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | $207.7K | Apr 15, 2025 |
| FY2011 | Dec 31, 2011 | $0 | Apr 2, 2012 |
| FY2011 | Dec 31, 2010 | $0 | Apr 2, 2012 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($4.69M) | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | ($6.98M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($9.94M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($4.60M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($872.8K) | Apr 14, 2022 |
| FY2020 | Dec 31, 2019 | ($413.9K) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $539.7K | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | ($67.7K) | Jul 26, 2019 |
| FY2017 | Dec 31, 2016 | ($271.3K) | Jul 24, 2019 |
| FY2016 | Dec 31, 2015 | ($106.9K) | Aug 15, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($4.09M) | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | ($6.90M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($9.94M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($4.53M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($914.7K) | Apr 14, 2022 |
| FY2020 | Dec 31, 2019 | ($386.1K) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($65.0K) | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | ($67.7K) | Jul 26, 2019 |
| FY2017 | Dec 31, 2016 | ($137.6K) | Jul 24, 2019 |
| FY2016 | Dec 31, 2015 | ($106.9K) | Aug 15, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $1.30M | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | $1.94M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $1.39M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $497.1K | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $489.2K | Apr 14, 2022 |
| FY2020 | Dec 31, 2019 | $263.5K | Apr 15, 2021 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2011 | Dec 31, 2011 | $82.2K | Apr 2, 2012 |
| FY2011 | Dec 31, 2010 | $76.2K | Apr 2, 2012 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($1.45M) | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | ($1.07M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($943.7K) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($799.1K) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($649.6K) | Apr 14, 2022 |
| FY2020 | Dec 31, 2019 | ($318.3K) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($55.8K) | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | ($69.0K) | Jul 26, 2019 |
| FY2017 | Dec 31, 2016 | ($119.4K) | Jul 24, 2019 |
| FY2015 | Dec 31, 2015 | ($120.1K) | Apr 18, 2016 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $7.0K | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | $30.9K | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $26.8K | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $8.9K | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $24.2K | Apr 14, 2022 |
| FY2020 | Dec 31, 2019 | $1.4K | Apr 15, 2021 |
| FY2011 | Dec 31, 2011 | $0 | Apr 2, 2012 |
| FY2011 | Dec 31, 2010 | $0 | Apr 2, 2012 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $16.12M | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | $10.20M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $10.23M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $1.59M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $458.2K | Apr 14, 2022 |
| FY2020 | Dec 31, 2019 | $620.2K | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $23.0K | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | $25.1K | Jul 26, 2019 |
| FY2017 | Dec 31, 2016 | $3.0K | Jul 24, 2019 |
| FY2016 | Dec 31, 2015 | $117.8K | Aug 15, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $5.45M | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | $3.87M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $3.95M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $3.11M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $2.44M | Apr 14, 2022 |
| FY2020 | Dec 31, 2019 | $1.25M | Apr 15, 2021 |
| FY2016 | Dec 31, 2016 | $835.6K | Aug 15, 2018 |
| FY2016 | Dec 31, 2015 | $679.1K | Aug 15, 2018 |
| FY2015 | Dec 31, 2014 | $454.4K | Apr 18, 2016 |
| FY2014 | Dec 31, 2013 | $413.1K | May 14, 2015 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $2.14M | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | $2.60M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $2.47M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($1.52M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($1.98M) | Apr 14, 2022 |
| FY2021 | Dec 31, 2019 | ($629.3K) | Apr 14, 2022 |
| FY2020 | Dec 31, 2018 | ($203.8K) | Apr 15, 2021 |
| FY2019 | Dec 31, 2017 | ($900.3K) | Apr 14, 2020 |
| FY2018 | Dec 31, 2016 | ($832.6K) | Jul 26, 2019 |
| FY2017 | Dec 31, 2015 | ($561.3K) | Jul 24, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2011 | Dec 31, 2011 | $0 | Apr 2, 2012 |
| FY2011 | Dec 31, 2010 | $47.83M | Apr 2, 2012 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($27.71M) | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | ($23.02M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($16.04M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($6.09M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($1.50M) | Apr 14, 2022 |
| FY2020 | Dec 31, 2019 | ($623.8K) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($25.65M) | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | ($26.19M) | Jul 26, 2019 |
| FY2017 | Dec 31, 2016 | ($26.12M) | Jul 24, 2019 |
| FY2016 | Dec 31, 2015 | ($25.85M) | Aug 15, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $63.2K | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | $46.4K | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $56.3K | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $46.0K | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $359.9K | Apr 14, 2022 |
| FY2020 | Dec 31, 2019 | $359.5K | Apr 15, 2021 |
| FY2016 | Dec 31, 2016 | $0 | Aug 15, 2018 |
| FY2016 | Dec 31, 2015 | $0 | Aug 15, 2018 |
| FY2013 | Dec 31, 2011 | $212 | Jun 2, 2014 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Apr 17, 2023 |
| FY2011 | Dec 31, 2011 | 0 | Apr 2, 2012 |
| FY2011 | Dec 31, 2010 | 0 | Apr 2, 2012 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 15, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 550.83B | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | 520.80B | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | 516.30B | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | 488.50B | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | 89.79B | Apr 14, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | 89.79B | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | 89.79B | Jul 26, 2019 |
| FY2017 | Dec 31, 2016 | 89.79B | Jul 24, 2019 |
| FY2016 | Dec 31, 2015 | 89.79B | Aug 15, 2018 |